Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Maestro what utter rubbish. It doesn’t matter whether they stay firm or not, it matters what is in the contract which you have no idea about.
It’s also not a profit warning, phase 2 not being activated was priced in. They never divulged information on 2021 revenue therefore it’s not a profit warning. Still expect them to make circa £180mil with a £290 mil MCAP and £100mil in the bank.
The certainty over the Q4 revenue has to be mentioned but it could only by £10mil, a drop in the ocean compared to the £300mil turn over for the year.
https://twitter.com/stevebennett17/status/1381563943261454336?s=21
Supposedly yourgene are providing the TF test:
"The Ion AmpliSeq SARS-CoV-2 Research Panel consists of two pools with amplicons ranging from 125 bp to 275 bp in length and covers >99% of the SARS-CoV-2 genome, including all serotypes. The assay is part of a fast, automated, and accurate targeted NGS workflow that enables coronavirus typing in under a day."
https://twitter.com/richard78398611/status/1381609781614551041?s=21
Thoughts? Don’t they manufacture tests for us....? They’ve kept the sequencing very quiet...?
One of the members of the telegram group mentioned Novacyt should maybe be a no reply Twitter account. Lots of potential customers see shorters, pi**ed off investors and derampers posts littering their feed. Not very professional.
Lots of benefits to the latter. Look at french company valuations / ours in comparison to all those solely listed on AIM, look at ODDO note as well. I would be jumping around with joy if we controlled the price rather than the bourse.
There’s an article about Chile today, 3rd highest jab ratio for population, yet they currently have over 1mil COVID cases active and 7000 cases per day growing.
Another article stating Pfizer isn’t effective against SA variant.
We called it months ago, vaccines are not the silver bullet that the Gov are portraying them as. Not good for us as a population but good for NCYT.
This is still the beginning for NCYT.
Market Capitalisation: £297.6m; Share price: 421p; Target Price: under review
• On Friday, diagnostic developer, Novacyt, provided a trading update and an update on its supply contract with the UK Department of Health and Social Care (DHSC).
• The Group announced that the DHSC has not agreed to an extension of a contract (first announced in September 2020) for the supply of Novacyt’s PCR instruments and COVID-19 test kits.
• As a result, Novacyt believes that revenue and profit for FY21 may be lower than current market expectations.
• The Group notes it has been supplying the DHSC with PROmateTM, the Group’s direct-to-PCR COVID-19 assay, in Q121.
• Novacyt and the DHSC are in dispute regarding the contract, which may have a material impact on Q420 revenue.
• The Group announced that revenue for the three months ended 31 March 2021 (Q121) was €83.0m (£72.6m).
• Approximately half of Q121 revenue was driven by sales to the DHSC with the remainder driven by international sales and
the Company’s private sector testing operations.
Whilst the lack of a contract extension is expected to impact FY21 revenues, this is mitigated by international sales and private sector testing operations which contributed to half of Q121 trading. The Group is continuing to rollout PROmateTM in hospitals, private sector settings and international markets as well as launching additional products over the year, such as lateral flow tests. The contract dispute is a disappointing outcome for both parties, however, Novacyt has taken legal advice and believes it has strong grounds to assert its contractual rights. Given the uncertainty regarding the DHSC contract and limited visibility over future sales we have withdrawn our forecasts and have put our target price under review.
I think the profit warning is based on broker predictions.
They still made circa £70mil Q1, 50% from non DHSC.
Therefore I expect minimum (based on rising global cases) of £70mil + 3 x £35mil = £175mil = EBITA £140mil.
Could also be based on potential some of the 2020 Q4 revenue due to the disagreement with the DHSC.
If there were a takeover approach coming it wouldn’t be on the gentlemanly type. Driving the price down etc is in the form of a hostile approach. That wouldn’t benefit shareholders in the same way.